# Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

> **NCT06006403** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 36 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Relapse Leukemia
- Refractory Leukemia

## Interventions

- **BIOLOGICAL:** CD123 targeted CAR-NK cells

## Key facts

- **NCT ID:** NCT06006403
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-08-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006403, "Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06006403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*